Saudi expert consensus on the management of acute asthma and COPD exacerbations with algorithm of aerosol drug delivery device recommendations
Abstract
Objective: To develop a practical, expert consensus for the management of acute asthma and chronic obstructive pulmonary disease (COPD) exacerbations in Saudi Arabia's Emergency Departments (EDs), addressing gaps in triage, diagnostic certainty, and aerosol delivery.
Methods: A modified expert consensus process with Delphi elements was employed. Eight multidisciplinary experts in pulmonary medicine, emergency medicine, and respiratory therapy, three of whom were affiliated with the Saudi Society of Emergency Medicine (SASEM), two of whom are authors of the Saudi initiative for Asthma (SINA) Guidelines, and three of whom are authors of the Saudi COPD guidelines, reviewed evidence-based presentations and formulated structured discussion questions before the meeting. The advisory board session (Riyadh, November 19, 2025) served as the formal consensus round, addressing ten predefined clinical questions across two moderated debate sessions, with formal voting on two key device-selection statements.
Results: The panel adopted a dual-phase severity classification: a binary "Non-Severe vs. Severe" model for rapid ED triage, followed by the four-tier SINA classification for clinical management. Pharmacological algorithms were standardized, prioritizing early corticosteroid therapy and optimizing bronchodilator dosing to mitigate toxicity. The panel reached a unanimous consensus that aerosol delivery device selection significantly influences treatment success; A-VMN was recommended…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.